What is the Saroglitazar?

Saroglitazar is , while it's Molecular Formula is C25H29NO4S. Saroglitazar, is a drug for the treatment of diabetic dyslipidemia and hypertriglyceridemia with Type 2 diabetes mellitus not controlled by statin therapy. Its trade name is Lipaglyn. It is also a 1,2-Diarylpyrroles derivative, which can be used in the preparation of Nonsteroidal anti-inflammatory drugs (NSAIDs).

What is the CAS number for Saroglitazar?

The CAS number of Saroglitazar is 495399-09-2.

What is Saroglitazar (495399-09-2) used for?

Saroglitazar is a dual agonist of PPARα and PPARγ (EC50s = 0.65 and 3,000 pM, respectively, in a transactivation assay in HepG2 cells). It decreases serum triglyceride, free fatty acid, and glucose levels in a db/db mouse model of diabetes when administered at doses ranging from 0.01 to 3 mg/kg per day for 12 days. It increases insulin sensitivity in an oral glucose challenge when administered at a dose of 1 mg/kg in db/db mice, as well as decreases LDL levels in hApoB100/hCETP mice and in hamsters fed a high-fat high-cholesterol diet. Saroglitazar (10 μM) reverses palmitic acid-induced decreases in the expression of superoxide dismutase 1 (SOD1), SOD2, glutathione peroxidase (GPX), and catalase and increases in TNF-α, IL-1β, and IL-6 expression in HepG2 cells. It decreases hepatic inflammation and steatosis in a mouse model of non-alcoholic steatohepatitis (NASH) induced by a choline-deficient high-fat diet when administered at a dose of 3 mg/kg and inhibits fibrosis in a mouse model of fibrosis induced by carbon tetrachloride.

What is the Saroglitazar?

Saroglitazar is , while it's Molecular Formula is C25H29NO4S. Saroglitazar, is a drug for the treatment of diabetic dyslipidemia and hypertriglyceridemia with Type 2 diabetes mellitus not controlled by statin therapy. Its trade name is Lipaglyn. It is also a 1,2-Diarylpyrroles derivative, which can be used in the preparation of Nonsteroidal anti-inflammatory drugs (NSAIDs).

What is the CAS number for Saroglitazar?

The CAS number of Saroglitazar is 495399-09-2.

What is Saroglitazar (495399-09-2) used for?

Saroglitazar is a dual agonist of PPARα and PPARγ (EC50s = 0.65 and 3,000 pM, respectively, in a transactivation assay in HepG2 cells). It decreases serum triglyceride, free fatty acid, and glucose levels in a db/db mouse model of diabetes when administered at doses ranging from 0.01 to 3 mg/kg per day for 12 days. It increases insulin sensitivity in an oral glucose challenge when administered at a dose of 1 mg/kg in db/db mice, as well as decreases LDL levels in hApoB100/hCETP mice and in hamsters fed a high-fat high-cholesterol diet. Saroglitazar (10 μM) reverses palmitic acid-induced decreases in the expression of superoxide dismutase 1 (SOD1), SOD2, glutathione peroxidase (GPX), and catalase and increases in TNF-α, IL-1β, and IL-6 expression in HepG2 cells. It decreases hepatic inflammation and steatosis in a mouse model of non-alcoholic steatohepatitis (NASH) induced by a choline-deficient high-fat diet when administered at a dose of 3 mg/kg and inhibits fibrosis in a mouse model of fibrosis induced by carbon tetrachloride.

Product classification

Contact us

Tel：+86-0533-2185556
Fax：+86-0533-2185556
Phone：+86 15965530500
Website：http://www.shandonghangyu.com/
Email：admin@hangyubiotech.com
Address：Room 2516, Dingcheng Building, Beijing Road, Zhangdian District, Zibo City, Shandong Province

495399-09-2

Product Name:Saroglitazar
Molecular Formula:C25H29NO4S
Molecular Weight:439.57

Inquiry

Product Details

Purity:99%

Factory supply good quality Saroglitazar 495399-09-2 with stock

Molecular Formula:C25H29NO4S
Molecular Weight:439.57
Boiling Point:621.0±55.0 °C(Predicted)
PKA:3.60±0.10(Predicted)
PSA：85.99000
Density:1.15±0.1 g/cm3(Predicted)
LogP:5.29660

495399-09-2 Relevant articles

NOVEL SALTS, CRYSTALLINE FORMS AND PREMIX OF HYPOLIPIDEMIC AGENT

-

Page/Page column 39-40; 41; 43; 46; 51-54, (2020/09/30)

Present invention relates to novel salts...

SYNERGISTIC COMPOSITIONS

-

Page/Page column 33; 34, (2015/01/16)

The present invention describes a synerg...

AN IMPROVED PROCESS FOR THE PREPARATION OF PYRROLE DERIVATIVES

-

Page/Page column 42; 43, (2015/03/28)

The present invention relates to an impr...

POLYMORPHIC FORM OF PYRROLE DERIVATIVE AND INTERMEDIATE THEREOF

-

, (2015/03/16)

The present invention relates to Sarogli...

495399-09-2 Process route

: 222555-06-8
ethyl (2S)-2-ethoxy-3-(4-hydroxyphenyl)propanoate

: 495399-09-2
(S)-2-ethoxy-3-(4-(2-(2-methyl-5-(4-(methylthio)phenyl)-1H-pyrrol-1-yl)ethoxy)phenyl)propanoic acid

Conditions

Conditions	Yield
Multi-step reaction with 2 steps 1.1: potassium carbonate / cyclohexane / 0.5 h / 45 - 55 °C / Inert atmosphere 1.2: 36 h / 75 - 85 °C 2.1: sodium hydroxide; water / ethanol / 3 h / 25 °C / Inert atmosphere With water; potassium carbonate; sodium hydroxide; In ethanol; cyclohexane;
Multi-step reaction with 3 steps 1.1: potassium carbonate / cyclohexane / 0.5 h / 45 - 55 °C / Inert atmosphere 1.2: 36 h / 75 - 85 °C 2.1: sodium hydroxide; water / ethanol / 3 h / Inert atmosphere 2.2: 1 h / Inert atmosphere 3.1: sodium hydroxide; water / ethanol / 3 h / 25 °C / Inert atmosphere 3.2: 1 h With water; potassium carbonate; sodium hydroxide; In ethanol; cyclohexane;
Multi-step reaction with 4 steps 1.1: potassium carbonate / cyclohexane / 0.5 h / 45 - 55 °C / Inert atmosphere 1.2: 36 h / 75 - 85 °C 2.1: sodium hydroxide; water / ethanol / 3 h / Inert atmosphere 2.2: 4.5 h / 0 - 45 °C / Inert atmosphere 3.1: hydrogenchloride / water; Isopropyl acetate / 25 °C / pH 2 - 3 / Inert atmosphere 3.2: 1 h / Inert atmosphere 4.1: sodium hydroxide; water / ethanol / 3 h / 25 °C / Inert atmosphere 4.2: 1 h With hydrogenchloride; water; potassium carbonate; sodium hydroxide; In ethanol; Isopropyl acetate; cyclohexane; water;

: 1392592-61-8
(S)-(-)α-1-phenylethylamine salt of (S)-α-ethoxy-4-[2-[-methyl-5-[4-(methylthio) phenyl]-1H-pyrrol-1-yl]ethoxy]benzene-propanoic acid

: 495399-09-2
(S)-2-ethoxy-3-(4-(2-(2-methyl-5-(4-(methylthio)phenyl)-1H-pyrrol-1-yl)ethoxy)phenyl)propanoic acid

Conditions

Conditions	Yield
With hydrogenchloride; water; In ethyl acetate; at 20 ℃; for 0.166667h; Solvent; Temperature; Inert atmosphere;
With hydrogenchloride; In Isopropyl acetate; water; at 25 ℃; pH=2 - 3;
With hydrogenchloride; water; In ethyl acetate; at 20 ℃; for 0.166667h; Inert atmosphere;

495399-09-2 Upstream products

1392592-61-8
(S)-(-)α-1-phenylethylamine salt of (S)-α-ethoxy-4-[2-[-methyl-5-[4-(methylthio) phenyl]-1H-pyrrol-1-yl]ethoxy]benzene-propanoic acid
222555-06-8
ethyl (2S)-2-ethoxy-3-(4-hydroxyphenyl)propanoate
494850-87-2
methanesulfonic acid 2-[2-methyl-5-(4-methylsulfanyl-phenyl)-pyrrol-1-yl]-ethyl ester

495399-09-2 Downstream products

1064453-40-2
(S)-2-ethoxy-3-(4-(2-(2-methyl-5-(4-(methylthio)phenyl)-1H-pyrrol-1-yl)ethoxy)phenyl)propanoic acid sodium salt
1392592-60-7
(S)-α-ethoxy-4-[2-[-methyl-5-[4-(methylthio)phenyl]-1H-pyrrol-1-yl]ethoxy]benzenepropanoic acid potassium salt

Relevant Products

Prasugrel
CAS：115473-15-9
OXACILLIN SODIUM
CAS：1173-88-2
Nsc 76049
CAS：1941-86-2
Mubritinib
CAS：366017-09-6